Published in J Cancer Res Clin Oncol on January 25, 2006
Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol (2010) 1.13
Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res (2011) 0.94
Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol (2008) 0.90
Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med (2013) 0.90
GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients. Breast Cancer Res (2007) 0.86
Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res (2007) 0.83
Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer. Nurs Res (2013) 0.77
Reducing Breast Cancer Recurrence: The Role of Dietary Polyphenolics. Nutrients (2016) 0.77
Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer. J Mol Cell Biol (2015) 0.75
In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator. Invest New Drugs (2014) 0.75
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 22.64
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 12.78
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med (1995) 6.44
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol (2005) 5.41
Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol (1998) 4.35
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol (2003) 3.90
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol (2005) 3.63
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol (2003) 3.58
Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat (2002) 3.19
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst (2003) 3.16
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Breast cancer diagnosis and screening. Am Fam Physician (2000) 2.63
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
Primary care for survivors of breast cancer. N Engl J Med (2000) 2.39
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol (2005) 2.30
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest (2001) 1.89
Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast (2004) 1.88
Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. Cancer (2001) 1.72
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer (2004) 1.31
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol (1996) 1.25
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer (2003) 1.20
Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer (2000) 1.12
Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol (2001) 1.06
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat (1997) 1.05
Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med (1986) 1.04
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res (2002) 1.01
Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer (2002) 0.85
Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol (2005) 0.83
Adjuvant chemotherapy for breast cancer: an update. Semin Oncol (2001) 0.81
Cardiac toxicity from antitumor therapy. Oncology (1980) 0.77
Taxanes in the adjuvant treatment of breast cancer: why not yet? J Natl Cancer Inst Monogr (2001) 0.75
Optimizing the use of anthracyclines in the adjuvant treatment of early-stage breast cancer. Clin Breast Cancer (2003) 0.75
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol (1999) 2.29
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol (2001) 2.25
The effect of hospital admission on the opinions and knowledge of elderly patients regarding cardiopulmonary resuscitation. Age Ageing (1997) 2.10
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97
Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol (1999) 1.96
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol (1999) 1.92
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol (2006) 1.85
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol (2011) 1.64
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen). J Allergy Clin Immunol (2000) 1.58
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst (2000) 1.54
Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness. Br J Cancer (2003) 1.51
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol (2000) 1.51
Walking sticks used by the elderly. Br Med J (Clin Res Ed) (1982) 1.49
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res (1989) 1.48
Surgeon workload and survival from breast cancer. Br J Cancer (2003) 1.45
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res (1992) 1.44
[Good results in periodic screening in women with increased risk of breast cancer; retrospective study]. Ned Tijdschr Geneeskd (1995) 1.44
Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res (1990) 1.43
Is thiamine deficiency in elderly people related to age or co-morbidity? Age Ageing (2000) 1.43
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet (2000) 1.42
The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem (1995) 1.42
Systemic adjuvant therapy for node-negative breast cancer. CMAJ (1989) 1.42
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol (1992) 1.39
[Chemotherapy in metastasized breast carcinoma]. Ned Tijdschr Geneeskd (1998) 1.38
Macrophage infiltration of breast tumours: a prospective study. J Clin Pathol (1977) 1.37
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol (2012) 1.37
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol (1994) 1.36
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer (1996) 1.34
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res (1989) 1.32
The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med (1985) 1.28
Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology (1988) 1.27
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer (1992) 1.26
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Advanced breast cancer and its prevention by screening. Br J Cancer (1992) 1.23
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet (1982) 1.20
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res (1995) 1.19
Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer (2006) 1.17
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer (2000) 1.16
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol (2010) 1.14
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res (1992) 1.14
High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab (1986) 1.13
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer (1996) 1.13
DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer (2005) 1.12
Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol (1998) 1.12
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst (1995) 1.12
Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet (2001) 1.09
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer (2001) 1.08
Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs (2001) 1.08
What do patients and their carers want to know about stroke? A two-year follow-up study. Clin Rehabil (1998) 1.07
Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr (1992) 1.07
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer (2001) 1.07
Inequalities in breast cancer care and outcome. Br J Cancer (1997) 1.05
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer (1997) 1.05
Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother (1984) 1.04
Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer (2009) 1.04
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (1995) 1.04
The effect of compliance on clinical outcomes for patients with dysphagia on videofluoroscopy. Dysphagia (2001) 1.03
Stromal influences on breast cancer cell growth. Br J Cancer (1992) 1.03
BRCA1 in the family: a case description of the psychological implications. Am J Med Genet (1997) 1.03
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol (2000) 1.02
Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group. J Med Genet (1999) 1.02
Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer (1989) 1.02
Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol (1987) 1.01
DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep (1981) 1.01
Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol (1993) 1.01
Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res (1986) 1.01
TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer (1996) 1.00
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res (1995) 0.99
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol (2009) 0.98
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer (1993) 0.98
Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol (1985) 0.98